Literature DB >> 28133242

[Effectiveness of Lenvatinib for Thyroid Cancer with Lung Metastases - Report of a Case].

Saki Nagashima1, Sadanori Matsuo, Mayumi Takahashi, Yasuko Umemoto, Tomohiro Hirano, Katsuhisa Enomoto, Kenichi Sakurai, Sadao Amano.   

Abstract

A 73-year-old woman visited our hospital 1 year 4 months ago because of multiple lung masses that were incidentally detected on CT. We subsequently conducted a whole body examination. Ultrasonography revealed multiple masses in her thyroid. We performed fine needle aspiration biopsy cytology(ABC), and the cytological diagnosis was papillary carcinoma. Total thyroidectomy and modified radical neck dissection were performed. Two months after the operation, cervical lymph nodes were enlarged, and she received I -131 radioisotope therapy. However, the lung masses became enlarged. Five months after operation, she was stared on lenvatinib therapy. The lung lesions did not progress during the 10 months after starting this therapy. In this case, lenvatinib was effective against metastatic thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28133242

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447

2.  Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.

Authors:  Renzhi Yu; Minghuan Wang; Xiuli Zhu; Zhe Sun; Aiying Jiang; Huixin Yao
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.